Indeed, during in vitro treatment as described here, CD7-negative malignant blasts survived and, in a phase I clinical trial, two of eight AML patients relapsed with CD7-negative leukemia after initially achieving a complete remission with CD7 CAR T cell therapy. This evidence concerns the gene CD7 and acute myeloid leukemia.